Emergent BioSolutions, Inc., CEO honored for vaccine work

Fuad El-Hibri, the chairman and chief executive officer of Emergent BioSolutions, Inc., was recently recognized as Biotech CEO of the Year during the Vaccine Industry Excellence Awards at the World Vaccine Congress.

The ViE awards honor the accomplishments of both companies and individuals in the global vaccine industry. The finalists for the category were evaluated based on their commitment to disease prevention and treatment, contribution to company performance, leadership, vision, communication, achievements in company positioning, industry influence and status.

“This award is a testament to the collective efforts of the Emergent BioSolutions team, who on a daily basis and all over the world, lives out the corporate mission – to protect life,” El-Hibri said. “Our team shares a passion and commitment to make vital contributions to address unmet and underserved medical needs. It is an honor to be recognized for the work that we do.”

Emergent Biosolutions, Inc., is a biotechnology company that develops and manufactures therapeutics and vaccines that are supplied to healthcare purchasers and providers for use in treating and preventing disease. Its investigational and marketed products target infectious diseases, autoimmune disorders and oncology.

The company recently began a Phase IIb clinical trial to test the efficacy of the MVA85A vaccine against tuberculosis in infants. The trial in Worcester, South Africa, involves 2,784 infants. It is being conducted by the University of Cape Town’s South African Tuberculosis Vaccine Initiative in partnership with Aeras Global TB Foundation and the Oxford-Emergent Tuberculosis Consortium.